Literature DB >> 3130088

Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the Spinhaler.

R M Auty1, K Brown, M G Neale, P D Snashall.   

Abstract

Sodium cromoglycate deposition has been studied following delivery of the drug by inhalation to six normal volunteers and two groups of ten patients using the Spinhaler. Plasma concentrations of the drug, and its urinary excretion have been related to the inhalation technique used for its delivery. An early peak concentration of sodium cromoglycate occurred in the plasma, thereafter the plasma concentration declined mono- or bi-exponentially with a terminal T1/2 of approximately 100 minutes in both patients and normal subjects. There was a marked between-subject variability in the plasma concentrations of sodium cromoglycate achieved, and in the areas under the plasma concentration-time curves of the drug. This reflects the variability between subjects in the amount of drug delivered to the respiratory tract. Most of this variability was due to differences in inhalation technique particularly with regard to inspiratory flow rate achieved and duration of breath-holding after inhalation. Thus careful instruction of patients is required to derive optimal dosing with sodium cromoglycate. It is recommended that patients inhale through the Spinhaler as rapidly as possible and then breath-hold for 10 seconds. These data provide a valuable background against which to study the relationship between the disposition of sodium cromoglycate, its site of action and its efficacy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3130088     DOI: 10.1016/0007-0971(87)90186-0

Source DB:  PubMed          Journal:  Br J Dis Chest        ISSN: 0007-0971


  10 in total

1.  Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion.

Authors:  O A Aswania; S A Corlett; H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

2.  Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for pharmacodynamic effect.

Authors:  N M Concessio; M M VanOort; M R Knowles; A J Hickey
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

Review 3.  Can lung deposition data act as a surrogate for the clinical response to inhaled asthma drugs?

Authors:  S P Newman
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

Review 4.  Deposition and effects of inhaled corticosteroids.

Authors:  Stephen P Newman
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Particle size selection device for use with the Turbohaler.

Authors:  M L Everard; S G Devadason; P N Le Souef
Journal:  Thorax       Date:  1996-05       Impact factor: 9.139

Review 6.  The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.

Authors:  Jeffry Weers; Andy Clark
Journal:  Pharm Res       Date:  2016-10-13       Impact factor: 4.200

7.  Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurized metered dose inhaler.

Authors:  S Newman; K Steed; G Hooper; A Källén; L Borgström
Journal:  Pharm Res       Date:  1995-02       Impact factor: 4.200

8.  Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report.

Authors:  Alan M Edwards; Hans Hagberg
Journal:  J Med Case Rep       Date:  2010-06-26

9.  Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization.

Authors:  Catherine H Richardson; Marcel de Matas; Harold Hosker; Rahul Mukherjee; Ian Wong; Henry Chrystyn
Journal:  Pharm Res       Date:  2007-05-18       Impact factor: 4.200

10.  Inspiratory flow patterns with dry powder inhalers of low and medium flow resistance in patients with pulmonary arterial hypertension.

Authors:  Mariana Faria-Urbina; Keith T Ung; Laurie Lawler; Lawrence S Zisman; Aaron B Waxman
Journal:  Pulm Circ       Date:  2021-05-13       Impact factor: 3.017

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.